- Patients
- Clinical Research
- Clinical trials
- STARSTRUCK 177Lu-TLX250-001
2023-08-22T00:00:00.000+10:00
Ongoing
STARSTRUCK
STARSTRUCK
Solid Tumors
Open label, single-arm, multicentre dose escalation (Part 1) and dose expansion (Part 2) study to evaluate different combinations of 3 radioactive dose levels of 177Lu-TLX250 administered intravenously with 3 different doses of peposertib in patients with CAIX-expressing solid tumours.
Open label, single-arm, multicentre dose escalation (Part 1) and dose expansion (Part 2) study to evaluate different combinations of 3 radioactive dose levels of 177Lu-TLX250 administered intravenously with 3 different doses of peposertib in patients with CAIX-expressing solid tumours.
Trial overview
Clinical Area
Theranostics
Disease / Condition
Basket - Solid tumours
Study Phase
Ib
Trial Identifiers
Registration number: NCT05868174 https://www.clinicaltrials.gov/study/NCT05868174
|